667
EUROPEAN UROLOGY 65 (2014) 665–670
classification enables the identification of distinct molecular alterations that may provide a subset of tumors with selective advantage. Additionally, the classification sheds light into early events that may render patients more susceptible to developing PCa and into the likelihood of aggressiveness. Together, WGS and the punctuated evolution model have the potential to be integrated into clinical practice. This development may support the clinician’s ability to identify patients at high risk of developing an aggressive disease and to diagnose, manage, and treat patients based on specific gene alterations.
Conflicts of interest: The authors have nothing to disclose.
Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma Motzer RJ, Hutson TE, Cella D, et al.
as the upper bound of the 95% CI of the HR. In this trial, noninferiority was assumed if the upper bound of the 95% CI of the HR was
EUROPEAN UROLOGY 65 (2014) 665–670
classification enables the identification of distinct molecular alterations that may provide a subset of tumors with selective advantage. Additionally, the classification sheds light into early events that may render patients more susceptible to developing PCa and into the likelihood of aggressiveness. Together, WGS and the punctuated evolution model have the potential to be integrated into clinical practice. This development may support the clinician’s ability to identify patients at high risk of developing an aggressive disease and to diagnose, manage, and treat patients based on specific gene alterations.
Conflicts of interest: The authors have nothing to disclose.
Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma Motzer RJ, Hutson TE, Cella D, et al.
as the upper bound of the 95% CI of the HR. In this trial, noninferiority was assumed if the upper bound of the 95% CI of the HR was
